tbuckley/cabot-search huggingface dataset:
Reversible Cerebral Vasoconstriction Syndrome vs Posterior Reversible Encephalopathy Syndrome
Authors: S. Ali Nabavizadeh, Arastoo Vossough
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abstract 15231: Effect of Hypertension and Diabetes on Severe Coronary Artery Disease
Authors: Young Jin Youn, Ji Hyun Lee, Jun-Won Lee, Min-Soo Ahn, Jang-Young Kim, Byung-Su Yoo, Seung-Hwan Lee, Junghan Yoon, Kyung-Hoon Choe
Journal: Circulation (2012)

Background - Hypertension and diabetes are well known risk factors for coronary artery disease and the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) sco...
Reinventing qualitative research
Authors: Gavin J Andrews
Journal: BMJ (2016)

I agree that The BMJ should not actively exclude qualitative research based on metrics,1 but what we need to consider is how qualitative research might be reinvented.

As McCormack explains,2 much of it is currently, using a sports analogy, formulaic “post-game” interrogation. We (researchers) go all out and find “the player” (disadvantaged patient) during a break from “the game” (illness episode) …
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Authors: J. Sun, J. Ahn, J. Lee, Y. Park, S. Lee, M. Ahn, K. Park
Journal: Journal of Clinical Oncology (2010)

e18062 Background: Skeletal-related events (SREs) cause significant pain and morbidity to many non-small cell lung cancer (NSCLC) patients. We try to evaluate the predictive factor of SREs in NSCLC patients with bone metastases. Methods: We retrospectively examined the medical charts of 273 patients diagnosed with bone metastases secondary to NSCLC. The predictive factor of SREs was analyzed using the first-event analyses and a survival-adjusted multiple-event analysis. In addition, the impact of the kind of systemic treatment on SREs was evaluated by comparing the incidence rates of SREs during epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy and cytotoxic chemotherapy. Results: Out of 273 patients with bone metastases, 171 (62.6%) had at least one SRE and 46 of these experienced multiple SREs. In the first-event analyses, a larger proportion of ever-smokers have experienced the SRE compared with never-smokers (odds ratio, 2.80: 95% CI, 1.32 to 6.00). In addition, ever-smokers (Hazard ratio [HR], 1.75: 95% CI, 1.05 to 2.92), patients without history of EGFR TKI therapy (HR, 2.12: 95% CI, 1.49 to 3.00) and patients with histology of nonadenocarcinoma (HR, 1.59: 95% CI, 1.14 to 2.22) had a shorter median time from bone metastasis to first SRE. In a survival-adjusted multiple-event analysis, clinical characteristics such as ever-smoking, nonadenocarcinoma, poor performance status (ECOG ≥ 2), and no history of EGFR TKI therapy were independent risk factor of development of SRE throughout the course of disease. The incidence rate of SREs was 4.4% per cycle of EGFR TKI therapy (39 SREs/891 cycles), which was significantly lower than 7.3% per cycle for cytotoxic chemotherapy (125 SREs/1719 cycles) (p = 0.004). Conclusions: Our data indicate that patients with characteristics such as ever-smoking, nonadenocarcinoma, poor performance status, and no history of treatment with EGFR TKI are more likely to have SRE, so more vigilant surveillance and prevention should be considered to these patients. No significant financial relationships to disclose.
Correlative Light‐Electron Microscopy Shows RGD‐Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity
Authors: Basmah A. Othman, Christina Greenwood, Ayman F. Abuelela, Anil A. Bharath, Shu Chen, Ioannis Theodorou, Trevor Douglas, Maskai Uchida, Mary Ryan, Jasmeen S. Merzaban, Alexandra E. Porter
Journal: Advanced Healthcare Materials (2016)

ZnO nanoparticles (NPs) are reported to show a high degree of cancer cell selectivity with potential use in cancer imaging and therapy. Questions remain about the mode by which the ZnO NPs cause cell death, whether they exert an intra‐ or extracellular effect, and the resistance among different cancer cell types to ZnO NP exposure. The present study quantifies the variability between the cellular toxicity, dynamics of cellular uptake, and dissolution of bare and RGD (Arg‐Gly‐Asp)‐targeted ZnO NPs by MDA‐MB‐231 cells. Compared to bare ZnO NPs, RGD‐targeting of the ZnO NPs to integrin αvβ3 receptors expressed on MDA‐MB‐231 cells appears to increase the toxicity of the ZnO NPs to breast cancer cells at lower doses. Confocal microscopy of live MDA‐MB‐231 cells confirms uptake of both classes of ZnO NPs with a commensurate rise in intracellular Zn 2+ concentration prior to cell death. The response of the cells within the population to intracellular Zn 2+ is highly heterogeneous. In addition, the results emphasize the utility of dynamic and quantitative imaging in understanding cell uptake and processing of targeted therapeutic ZnO NPs at the cellular level by heterogeneous cancer cell populations, which can be crucial for the development of optimized treatment strategies.
<i>In vivo</i>reflectance confocal microscopy characterization of silver deposits in localized cutaneous argyria
Authors: P. García-Martínez, D. López Aventín, S. Segura, I. Gómez-Martín, J. Lloreta, J. Ibáñez, J.J. Elvira, R.M. Pujol
Journal: British Journal of Dermatology (2016)

Localized cutaneous argyria is a rare condition secondary to skin deposition of silver following exposure to substances containing this metal. The clinical appearance and dermoscopy findings require deep melanocytic lesions and particularly melanoma metastasis to be ruled out. Silver deposits are usually confirmed by scanning electron microscopy and/or energy‐dispersive X‐ray spectroscopy. Herein we describe the in vivo reflectance confocal microscopy (RCM) features observed in one case of localized cutaneous argyria. These features include the presence of a hyperrefractile network in the papillary dermis and a periadnexal dotted bright pattern. In vivo RCM might be a useful tool for an early diagnosis of this uncommon entity.
Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
Authors: Nele Adriaenssens, Mark De Ridder, Jan Lamote, Christel Fontaine, Hilde Van Parijs, Guy Storme, Harijati Versmessen, Geertje Miedema, Jacques De Greve, Vincent Vinh-Hung
Journal: Journal of Clinical Oncology (2016)

247 Background: Breast cancer is nowadays the most common cause of cancer death in the female population. A very commonly used treatment is radiotherapy (RT). Due to improvements of medical imaging and RT, a combination can be used resulting in image guided radiotherapy (TT). The aim of the present study is to investigate the difference in health related quality of life (HRQoL) of breast cancer patients before and 3 years after post-operative conventional radiotherapy (CRT) and TT. Methods: 120 participating patients were randomly allocated to either CRT or TT. The CRT group received 50Gy/25 fractions over a 5 week period (2Gy/fraction) and an additional boost of 16Gy in 8 fractions over 2 weeks. The TT group received 42 Gy in 15 fractions over 3 weeks (2.8 Gy/fraction) and simultaneously an integrated boost of 0,6Gy/fraction. HRQoL was evaluated using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and -BR23 (breast cancer module). Questionnaires were filled in before treatment (T0), right after finishing RT (T1) and at 3 months (T2), 1 year (T3), 2 years (T4) and 3 years (T5) follow up. Results: At T1 no statistically significant differences between the two treatment arms were found except global health status for which TT group scored worse than CRT. At T5, less severe constipation, diarrhoea, breast symptoms, upset by hair loss and more severe insomnia was found in TT compared to CRT, but the differences did not reach significance. Functional scales were comparable in treatment arms. Conclusions: Between the two treatment arms, no statistically significant differences were found at T5 but clinically meaningful differences in symptom scales favoured TT. Our study confirms the preliminary results of Versmessen et al. (BMC Cancer, 2012) in particular that a shorter more intensive fractionation schedule, using TT did not impair HRQoL in breast cancer patients. Clinical trial information: NCT00459628.
Premature Mortality and Schizophrenia—The Need to Heal Right From the Start
Authors: Katherine Samaras, Christoph U. Correll, Jackie Curtis
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Short-Term Spatial Memory Deficits in Men Arrested for Driving While Intoxicated
Authors: Eric W. Fine, Robert A. Steer
Journal: American Journal of Psychiatry (1979)

In the light of the fact that ethyl alcohol can cause damage to the brain, especially in the area of motor control, a study of the incidence of alcohol-related neuropsychological impairment in individuals arrested for driving while intoxicated (DWI) would be of great value. The authors report on 100 DWI offenders given a Memory-for Designs Test: 33% of the offenders were in the borderline range for organicity and a further 24% were in the critical range. Although they advise caution in interpreting these data, the authors point out a number of implications their analyses have for those interested in alcohol-related highway safety programs.
Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta‐analysis of RCTs
Authors: Eric M. Ammann, Cole B. Haskins, Kelsey M. Fillman, Rebecca L. Ritter, Xiaomei Gu, Scott K. Winiecki, Ryan M. Carnahan, James C. Torner, Bruce H. Fireman, Michael P. Jones, Elizabeth A. Chrischilles
Journal: American Journal of Hematology (2016)

Prior case reports and observational studies indicate that intravenous immune globulin (IVIg) products may cause thromboembolic events (TEEs), leading the FDA to require a boxed warning in 2013. The effect of IVIg treatment on the risk of serious TEEs (acute myocardial infarction, ischemic stroke, or venous thromboembolism) was assessed using adverse event data reported in randomized controlled trials (RCTs) of IVIg. RCTs of IVIg in adult patients from 1995 to 2015 were identified from Pubmed, Embase, ClinicalTrials.Gov, and two large prior reviews of IVIg's therapeutic applications. Trials at high risk of detection or reporting bias for serious adverse events were excluded. 31 RCTs with a total of 4,129 participants (2,318 IVIg-treated, 1,811 control) were eligible for quantitative synthesis. No evidence was found of increased TEE risk among IVIg-treated patients compared with control patients (odds ratio = 1.10, 95% CI: 0.44, 2.88; risk difference = 0.0%, 95% CI: -0.7%, 0.7%, I(2) = 0%). No significant increase in risk was found when arterial and venous TEEs were analyzed as separate endpoints. Trial publications provided little specific information concerning the methods used to ascertain potential adverse events. Care should be taken in extrapolating the results to patients with higher baseline risks of TEE. Am. J. Hematol. 91:594-605, 2016. © 2016 Wiley Periodicals, Inc.
Delayed start of adjuvant 5-FU/leucovorin based chemotherapy in colon cancer is safe up to 12 weeks postoperatively
Authors: G. Carlsson, P. Albertsson, B. Gustavsson
Journal: Journal of Clinical Oncology (2007)

4056 Background: Postoperatively adjuvant chemotherapy with 5-Fluorouracil modulated by leucovorin alone or in combination with Oxaliplatin significantly reduce the risk of recurrence and prolong the disease free survival (DFS) in patients with a radical resection for colonic carcinoma. In all reported studies the chemotherapy has started within 6–8 weeks after surgery. Due to complications following surgery it is not always possible to start adjuvant chemotherapy within this time frame. The aim of the present retrospective study was to investigate the effect on risk of recurrence and effect on DFS in patients treated in clinical routine practice in one single institution. Methods: Between 1992 and 2004, 234 patients (121 females, 113 males) with a median age of 66 years (range 25–84 years) received weekly bolus 5-FU/leucovorin postoperatively for 6 months. 211 (90.2%) had a Dukes′ C tumour and 23 (9.8%) high risk Dukes′ B tumour. The median time from surgery and start of adjuvant therapy was 71 days (range 30–190 days). Patients were divided in three groups, where chemotherapy started within 6 weeks, 8 weeks and 12 weeks after surgery and the frequency of recurrent disease and DFS were compared between these groups. Results: Medium follow-up was 35.6 months (range 2,7- 140.6 months). Five patients (21.7%) with Dukes′ B tumours and 76 patients (36.0%) with Dukes′ C tumours recurred during the follow-up period. There were no differences in the proportion of Dukes′ B and C tumours between the three groups. Recurrent disease was more frequent but no significant difference in patients that started within 6 weeks (52.6%) compared with patients that started within 8 weeks (45.5%) and 12 weeks (35.5%). In all three groups there was a tendency to better DFS in patients that started later than 6 or 8 weeks, but these differences were not significant. Conclusions: Starting adjuvant 5-Fluorouracil/leucovorin alone later than 6–8 weeks do not negatively effect the risk of recurrent disease or DFS. No significant financial relationships to disclose.
Development of her2-antagonistic peptides as novel anti-breast cancer drugs by in silico methods
Authors: H. Nakajima, N. Mizuta, K. Sakaguchi, I. Fujiwara, A. Yoshimori, R. Takasawa, S. Tanuma
Journal: Journal of Clinical Oncology (2008)

14014 Background: The overexpression of HER2 in breast cancer correlates well with increased tumor growth and metastatic potential, and thereby poor long-term survival for the patients. Therefore, therapeutic approaches are being developed to block the effects of HER2 overexpression in breast cancer by a monoclonal antibody, called trastuzumab. Based on these results, we are trying to design and produce antibody-mimetic peptide molecules using our in silico design method. Here, we report the creation of a novel peptide (HRAP: HER2 Reactive Peptide) that is able to antagonize HER2 signaling pathway. Methods: An antagonistic peptide called HRAP that binds to the human HER2 molecule was designed by our computational method. Peptides were synthesized by a peptide synthesizer. Human breast cancer cell lines, i.e. KPL-4, MDA231, BT-474, and SKBR-3, which express HER2 at various levels were used in this study. Cell proliferation was assayed using BrdU kit. Cell viability was measured by an MTT assay. Immunodetection of various protein expressions were performed by western blotting. Results: In silico docking study demonstrated the specific interaction of HRAP with the dimerization domain in the HER2 molecule. Interestingly, HRAP inhibited proliferation of HER2-overexpressed human breast cancer cell lines. However, it had little cellular cytotoxicity (apoptosis inducibility). The cell proliferation inhibition was associated with the suppression of phosphorylation of PTEN and Akt. Conclusions: HRAP is the first HER2-binding small peptide antagonist rationally designed by a computer-aided method and is useful for the development of peptide mimetics to generate novel anti-breast cancer drugs for HER2 expressing tumors. No significant financial relationships to disclose.
In situ radiation sensitivity of recombinant human granulocyte colony- stimulating factor-recruited murine circulating blood and bone marrow progenitors (colony-forming unit [CFU]-granulocyte-macrophage and CFU- megakaryocyte): evidence for possible biologic differences between mobilized blood and bone marrow
Authors: S Scheding, JE Media, MA KuKuruga, A Nakeff
Journal: Blood (1996)
Effects of age on the role of atrial natriuretic factor in renal adaptation to physiologic variations of dietary salt intake.
Authors: D Leosco, N Ferrara, P Landino, G Romano, S Sederino, F Cacciatore, G Longobardi, A Dal Canton, F Rengo
Journal: Journal of the American Society of Nephrology (1996)

The effects of normal, low, and high dietary salt intake on basal atrial natriuretic factor plasma levels, plasma renin activity, and aldosterone were evaluated in seven young (Group 1), seven middle-aged (Group 2), and seven elderly healthy volunteers (Group 3). In all subjects, progressively higher doses of human alpha-atrial natriuretic factor were infused at low-sodium diet conditions to obtain hormone plasma values during infusion similar to those obtained in the same subjects at high-sodium diet conditions. Atrial natriuretic factor plasma values were significantly higher in Group 3 than in the other two groups at both normal- and high-salt diet conditions, and at all steps of the infusion study. At low-sodium diet conditions, peptide concentrations averaged 23.2 +/- 6.2 in Group 3, 26.2 +/- 1.9 in Group 2, and 19.1 +/- 3.9 pg/mL in Group 1 (P = not significant between groups). Hormone plasma values at high-salt diet conditions averaged 47 +/- 6.9 pg/mL in Group 1, 60 +/- 6.5 pg/mL in Group 2, and 136.3 +/- 14.6 pg/mL in Group 3. Each value was not significantly different from the corresponding value gained at an infusion step of 2 ng/min per kg in Group 1 and 2 (57.1 +/- 11.9 and 62.7 +/- 6.5 pg/mL, respectively), and of 1 ng/min per kg (139.1 +/- 22.2 pg/mL) in Group 3. At these infusion steps and at high-salt diet conditions, the urinary sodium excretion rate was, respectively, 0.185 +/- 0.02 and 0.311 +/- 0.02 mEq/min in Group 1, 0.168 +/- 0.01 and 0.300 +/- 0.02 mEq/min in Group 2, and 0.110 +/- 0.01 and 0.256 +/- 0.01 mEq/min in Group 3. Hormone infusion induced a progressive fall of plasma renin activity and aldosterone level in all groups. By experimentally increasing plasma concentrations of atrial natriuretic factor in a low-salt diet condition to the levels occurring physiologically in a high-salt diet condition, a significant rise in urinary sodium excretion rate is evoked, which accounts for 52% in young, 47% in middle-aged, and 30% in older subjects of the rise that is necessary to balance the increased salt intake.
Epidemiological aspects of tuberculosis in children in Romania
Authors: Cristian Didilescu, Nicoleta Cioran, Domnica Ioana Chiotan, Gilda Popescu, Gheorghe Murgoci, Constantin Marica
Journal: European Respiratory Journal (2013)

Objective: Investigation of epidemiological aspects of TB in children, is a matter of concern, given the difficulties of diagnosis and still greater number of illnesses.

Material and method : Have been collected and analyzed the data contained in the National Electronic Register of TB Control Programme.

Results : In Romania. consistent with the gradual decrease in TB endemic level in an overall incidence of 142.2% ooo in 2002 to 82.8% ooo in 2011, the incidence of TB in children (0-14 years) dropped steadily from 47.2% ooo in the same year peak  2002 to 23.6% ooo in 2011. In absolute numbers (number of recorded cases per year), there was a decrease in cases from 1809 in 2002 to 776 cases in 2011. Distribution by county of TB disease in children show variations between these, explanations may be related to the differences in the various territories offer bacilli (contagious cases prevalence) and by deficiencies in the detection of cases and lack of rigor in diagnosis (in 2011 variations from 2.5% ooo to 53.5% ooo). The number of serious cases of TB in children (meningoencephalitis, miliary, cavitary) still maintains a constant high, which demonstrates gravity of TB endemia in our country (65 in 2011).

Conclusion : Decrease in TB disease among infant population between 2002-2011, is the consequence of implementing measures under the National Tuberculosis Control Program, a broadening of the DOTS strategy in 2005. Accessibility to health services specialized in pediatric pulmonology, ensuring their proper endowment, ensuring rigor diagnosis of tuberculosis in children.
Fel d 1 Peptide Immunotherapy Ameliorates Both Cat and Ovalbumin Responses, in a Dual Allergen Murine Model of Allergic Airways Disease
Authors: Daniel M. Moldaver, Mantej S. Bharhani, Christopher D. Rudulier, Jennifer Wattie, Mark D. Inman, Mark Larché
Journal: Journal of Allergy and Clinical Immunology (2016)